pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioSpace·Sep 10·1 min read
save

Takeda R&D chief Andy Plump to retire in June 2027 after 12-year tenure

Sep 10, 2026·read at BioSpace ↗Neutral

Takeda announced that its longstanding head of research and development, Andy Plump, will step down and retire in June 2027.

Plump has been with the Japanese drugmaker for about 12 years, leading its global R&D organization for more than a decade, and will remain on the board until his retirement.

He will continue to run R&D until a successor is named, and the company says the transition will be planned to keep continuity and momentum.

The leadership change follows a broader transformation that began in 2024, including a major reorganization and the elimination of roughly 4,500 jobs across Takeda’s operations.

source

This writeup was produced by pharmadog from original reporting by BioSpace.

Original headline: “Takeda’s long-term R&D head announces exit after major pipeline reorganization”

read at BioSpace ↗
684 words · retrieved Sep 10
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING3SanofiVera Therapeutics, Inc.
drugs
Small Moleculeszasocitinib
topics
Approval2Monoclonal Antibody2Psoriasis2Cell TherapyDermatologyTYK2

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Sep 286 immunology targets to sustain a mammoth I&I marketBioSpace
  • 1d agoTango plans 14% workforce cut, mainly of research staffBioSpace
  • Sep 10Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successesFierce Biotech
  • Jun 11Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head testBioPharma Dive